Allowing for differences in array coverage, we found that genes on this HES6-associated signature list were consistently enriched in DEG lists comparing metastatic or castrate-resistant tumours with benign or normal tissue (Supplementary Fig S10B and C). This evidence concerns the gene HES6 and neoplasm.